CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is a commercial-stage biopharmaceutical company focused on oncology, which became publicly traded through a business combination with TenX Keane Acquisition Corp, a SPAC that completed its initial public offering in 2021. The company was formed as a spinout of Citius Pharmaceuticals and holds LYMPHIR (denileukin diftitox), an FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma. On August 14, 2026, Citius Oncology filed a 424B3 prospectus supplement with the SEC under accession number 0001213900-26-090293. The company operates in the oncology segment of the specialty biopharmaceutical sector. Visit SpacDesk and sign up for a free account to access the full filing history, deal terms, and real-time data on TENK and hundreds of other SPAC transactions.